Specifically, treatment was found to significantly increase trabecular bone density and reduce ACP5+ osteoclast numbers suggesting anti-resorptive effects in vivo.153 While these studies were not conducted in a setting of cancer-induced bone disease, the anti-tumor effects noted with the first generation EIF2AK3 inhibitor, suggests potential application in cancer-induced osteolytic bone disease.185,186. The gene discussed is ACP5; the disease is neoplasm.